Harbor Investment Advisory LLC Decreases Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Harbor Investment Advisory LLC reduced its position in shares of Zoetis Inc. (NYSE:ZTS) by 17.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,547 shares of the company’s stock after selling 1,374 shares during the period. Harbor Investment Advisory LLC’s holdings in Zoetis were worth $1,067,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Darwin Wealth Management LLC bought a new stake in shares of Zoetis in the 3rd quarter worth approximately $31,000. First Personal Financial Services bought a new stake in Zoetis in the third quarter valued at $33,000. Capital Performance Advisors LLP purchased a new position in Zoetis during the 3rd quarter valued at $33,000. Dunhill Financial LLC raised its holdings in Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after purchasing an additional 75 shares in the last quarter. Finally, Quarry LP lifted its position in shares of Zoetis by 273.2% in the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after purchasing an additional 153 shares during the period. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Up 1.0 %

NYSE:ZTS opened at $167.50 on Wednesday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The firm has a market cap of $75.57 billion, a P/E ratio of 31.49, a P/E/G ratio of 2.55 and a beta of 0.89. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.53. The firm has a 50-day simple moving average of $170.73 and a two-hundred day simple moving average of $179.95.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.46 by $0.12. The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same quarter last year, the firm earned $1.36 earnings per share. Analysts predict that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, January 21st will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.19%. This is an increase from Zoetis’s previous quarterly dividend of $0.43. The ex-dividend date of this dividend is Tuesday, January 21st. Zoetis’s dividend payout ratio (DPR) is presently 37.59%.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ZTS. UBS Group assumed coverage on shares of Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target on the stock. Stifel Nicolaus decreased their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. JPMorgan Chase & Co. increased their price objective on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Finally, Leerink Partners started coverage on shares of Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price on the stock. One analyst has rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $211.89.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.